Robert J. Marlowe

No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer

Frederik A. Verburg, Marcel P. M. Stokkel, Christian Düren et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2009 · 110 citations

Medicine, Nuclear Medicine, Oncology +15

124I-PET dosimetry in advanced differentiated thyroid cancer: Therapeutic impact

Walter Jentzen, Rainer Görges, T. Petrich et al. · Nuklearmedizin - NuclearMedicine · 2007 · 107 citations

Medicine, Nuclear Medicine, Oncology +17

177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)

Fadi Khreish, Zaidoon Ghazal, Robert J. Marlowe et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2021 · 89 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Twenty-Five Years After Chernobyl: Outcome of Radioiodine Treatment in Children and Adolescents With Very High-Risk Radiation-Induced Differentiated Thyroid Carcinoma

Christoph Reiners, Johannes Biko, Heribert Haenscheid et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 82 citations

Medicine, Endocrinology, Oncology +17

Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons

Lutz S. Freudenberg, Walter Jentzen, T. Petrich et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2010 · 70 citations

Medicine, Nuclear Medicine, Radiology +16